SNYNF - GoodRx to offer Sanofi's Lantus insulin product at $35
2023-10-19 09:58:30 ET
More on Sanofi, GoodRx, etc.
- GoodRx Faces Challenges In Subscription Plans, But Its Valuation Already Prices This In
- GoodRx Stock: Earnings Momentum Keeps It Interesting
- Sanofi: 3 Reasons For A Buy
- Sanofi presents encouraging data on atopic dermatitis drug
- Mirati Therapeutics soars on report of Sanofi takeover interest
For further details see:
GoodRx to offer Sanofi’s Lantus insulin product at $35